Comparative Pharmacology
Head-to-head clinical analysis: CURRETAB versus ENDOMETRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CURRETAB versus ENDOMETRIN.
CURRETAB vs ENDOMETRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
Progesterone is a steroid hormone that binds to progesterone receptors in the endometrium, inducing secretory changes, decreasing uterine contractility, and supporting pregnancy maintenance.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
Vaginal tablet: 100 mg twice daily starting on day 15 of a 28-day cycle for 12 weeks.
None Documented
None Documented
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Terminal elimination half-life is approximately 12-15 hours, supporting twice-daily dosing for endometrial support.
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Primarily renal (50-60% as metabolites, <10% unchanged); fecal (20-30%) via biliary excretion.
Category C
Category C
Progestin
Progestin